{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:55:53Z","timestamp":1790949353062,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,3,20]],"date-time":"2017-03-20T00:00:00Z","timestamp":1489968000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1038\/nm.4310","type":"journal-article","created":{"date-parts":[[2017,3,20]],"date-time":"2017-03-20T15:57:34Z","timestamp":1490025454000},"page":"472-482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia"],"prefix":"10.1038","volume":"23","author":[{"given":"Meenu","family":"Kesarwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Kincaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Gomaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Rohrabaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad F","family":"Bouso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahir","family":"Latif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kakajan","family":"Komurov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C","family":"Mulloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A","family":"Cancelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8162-6758","authenticated-orcid":false,"given":"H Leighton","family":"Grimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Azam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,20]]},"reference":[{"key":"BFnm4310_CR1","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley, G.Q., Van Etten, R.A. & Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science 247, 824\u2013830 (1990).","journal-title":"Science"},{"key":"BFnm4310_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker, B.J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2, 561\u2013566 (1996).","journal-title":"Nat. Med."},{"key":"BFnm4310_CR3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc3317","volume":"12","author":"T O'Hare","year":"2012","unstructured":"O'Hare, T., Zabriskie, M.S., Eiring, A.M. & Deininger, M.W. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat. Rev. Cancer 12, 513\u2013526 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnm4310_CR4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot, P. et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109, 58\u201360 (2007).","journal-title":"Blood"},{"key":"BFnm4310_CR5","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon, F.X. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11, 1029\u20131035 (2010).","journal-title":"Lancet Oncol."},{"key":"BFnm4310_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross, D.M. et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122, 515\u2013522 (2013).","journal-title":"Blood"},{"key":"BFnm4310_CR7","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1182\/blood-2004-03-1114","volume":"105","author":"S Chu","year":"2005","unstructured":"Chu, S. et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 105, 2093\u20132098 (2005).","journal-title":"Blood"},{"key":"BFnm4310_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrc2368","volume":"8","author":"M Savona","year":"2008","unstructured":"Savona, M. & Talpaz, M. Getting to the stem of chronic myeloid leukaemia. Nat. Rev. Cancer 8, 341\u2013350 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnm4310_CR9","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","volume":"112","author":"M Azam","year":"2003","unstructured":"Azam, M., Latek, R.R. & Daley, G.Q. Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112, 831\u2013843 (2003).","journal-title":"Cell"},{"key":"BFnm4310_CR10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1056\/NEJMra044389","volume":"353","author":"DS Krause","year":"2005","unstructured":"Krause, D.S. & Van Etten, R.A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353, 172\u2013187 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnm4310_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1126\/science.1073096","volume":"297","author":"IB Weinstein","year":"2002","unstructured":"Weinstein, I.B. Cancer. Addiction to oncogenes\u2014the Achilles heal of cancer. Science 297, 63\u201364 (2002).","journal-title":"Science"},{"key":"BFnm4310_CR12","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/nm1009-1158","volume":"15","author":"CL Sawyers","year":"2009","unstructured":"Sawyers, C.L. Shifting paradigms: the seeds of oncogene addiction. Nat. Med. 15, 1158\u20131161 (2009).","journal-title":"Nat. Med."},{"key":"BFnm4310_CR13","doi-asserted-by":"publisher","first-page":"280","DOI":"10.15252\/embr.201439949","volume":"16","author":"R Pagliarini","year":"2015","unstructured":"Pagliarini, R., Shao, W. & Sellers, W.R. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep. 16, 280\u2013296 (2015).","journal-title":"EMBO Rep."},{"key":"BFnm4310_CR14","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/S1471-4892(02)00178-9","volume":"2","author":"A Reddy","year":"2002","unstructured":"Reddy, A. & Kaelin, W.G., Jr. Using cancer genetics to guide the selection of anticancer drug targets. Curr. Opin. Pharmacol. 2, 366\u2013373 (2002).","journal-title":"Curr. Opin. Pharmacol."},{"key":"BFnm4310_CR15","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrc1691","volume":"5","author":"WG, Kaelin Jr.","year":"2005","unstructured":"Kaelin, W.G., Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5, 689\u2013698 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnm4310_CR16","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1091\/mbc.e02-11-0732","volume":"14","author":"A Kamb","year":"2003","unstructured":"Kamb, A. Consequences of nonadaptive alterations in cancer. Mol. Biol. Cell 14, 2201\u20132205 (2003).","journal-title":"Mol. Biol. Cell"},{"key":"BFnm4310_CR17","doi-asserted-by":"publisher","first-page":"10031","DOI":"10.1073\/pnas.191379498","volume":"98","author":"GB Mills","year":"2001","unstructured":"Mills, G.B., Lu, Y. & Kohn, E.C. Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP\/RAFT\/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98, 10031\u201310033 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm4310_CR18","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.bcp.2010.03.001","volume":"80","author":"SV Sharma","year":"2010","unstructured":"Sharma, S.V. & Settleman, J. Exploiting the balance between life and death: targeted cancer therapy and \u201concogenic shock\u201d. Biochem. Pharmacol. 80, 666\u2013673 (2010).","journal-title":"Biochem. Pharmacol."},{"key":"BFnm4310_CR19","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1101\/gad.1609907","volume":"21","author":"SV Sharma","year":"2007","unstructured":"Sharma, S.V. & Settleman, J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21, 3214\u20133231 (2007).","journal-title":"Genes Dev."},{"key":"BFnm4310_CR20","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin, A.S. et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 121, 396\u2013409 (2011).","journal-title":"J. Clin. Invest."},{"key":"BFnm4310_CR21","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nature11183","volume":"487","author":"R Straussman","year":"2012","unstructured":"Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500\u2013504 (2012).","journal-title":"Nature"},{"key":"BFnm4310_CR22","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nature11249","volume":"487","author":"TR Wilson","year":"2012","unstructured":"Wilson, T.R. et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505\u2013509 (2012).","journal-title":"Nature"},{"key":"BFnm4310_CR23","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/leu.2008.337","volume":"23","author":"D Bruennert","year":"2009","unstructured":"Bruennert, D. et al. Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy. Leukemia 23, 983\u2013985 (2009).","journal-title":"Leukemia"},{"key":"BFnm4310_CR24","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/nrc1209","volume":"3","author":"R Eferl","year":"2003","unstructured":"Eferl, R. & Wagner, E.F. AP-1: a double-edged sword in tumorigenesis. Nat. Rev. Cancer 3, 859\u2013868 (2003).","journal-title":"Nat. Rev. Cancer"},{"key":"BFnm4310_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00018-012-1041-2","volume":"70","author":"A Lawan","year":"2013","unstructured":"Lawan, A., Shi, H., Gatzke, F. & Bennett, A.M. Diversity and specificity of the mitogen-activated protein kinase phosphatase-1 functions. Cell. Mol. Life Sci. 70, 223\u2013237 (2013).","journal-title":"Cell. Mol. Life Sci."},{"key":"BFnm4310_CR26","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd2289","volume":"6","author":"KL Jeffrey","year":"2007","unstructured":"Jeffrey, K.L., Camps, M., Rommel, C. & Mackay, C.R. Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat. Rev. Drug Discov. 6, 391\u2013403 (2007).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnm4310_CR27","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.bbagrm.2013.02.003","volume":"1829","author":"SA Brooks","year":"2013","unstructured":"Brooks, S.A. & Blackshear, P.J. Tristetraprolin (TTP): interactions with mRNA and proteins, and current thoughts on mechanisms of action. Biochim. Biophys. Acta 1829, 666\u2013679 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnm4310_CR28","first-page":"925","volume":"13","author":"K Dorfman","year":"1996","unstructured":"Dorfman, K. et al. Disruption of the erp\/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP\/MKP-1-deficient fibroblasts. Oncogene 13, 925\u2013931 (1996).","journal-title":"Oncogene"},{"key":"BFnm4310_CR29","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/ng859","volume":"30","author":"J Zhang","year":"2002","unstructured":"Zhang, J. et al. c-fos regulates neuronal excitability and survival. Nat. Genet. 30, 416\u2013420 (2002).","journal-title":"Nat. Genet."},{"key":"BFnm4310_CR30","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/nature07737","volume":"458","author":"C Zhao","year":"2009","unstructured":"Zhao, C. et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458, 776\u2013779 (2009).","journal-title":"Nature"},{"key":"BFnm4310_CR31","doi-asserted-by":"publisher","first-page":"3806","DOI":"10.1073\/pnas.87.10.3806","volume":"87","author":"LJ Ransone","year":"1990","unstructured":"Ransone, L.J., Visvader, J., Wamsley, P. & Verma, I.M. Trans-dominant negative mutants of Fos and Jun. Proc. Natl. Acad. Sci. USA 87, 3806\u20133810 (1990).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm4310_CR32","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/nchembio.190","volume":"5","author":"G Molina","year":"2009","unstructured":"Molina, G. et al. Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nat. Chem. Biol. 5, 680\u2013687 (2009).","journal-title":"Nat. Chem. Biol."},{"key":"BFnm4310_CR33","doi-asserted-by":"publisher","first-page":"5292","DOI":"10.1073\/pnas.88.12.5292","volume":"88","author":"TS Huang","year":"1991","unstructured":"Huang, T.S., Lee, S.C. & Lin, J.K. Suppression of c-Jun\/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA 88, 5292\u20135296 (1991).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm4310_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0304-3835(97)00543-0","volume":"127","author":"S Park","year":"1998","unstructured":"Park, S., Lee, D.K. & Yang, C.H. Inhibition of fos-jun-DNA complex formation by dihydroguaiaretic acid and in vitro cytotoxic effects on cancer cells. Cancer Lett. 127, 23\u201328 (1998).","journal-title":"Cancer Lett."},{"key":"BFnm4310_CR35","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1007\/s11095-009-9955-6","volume":"26","author":"S Padhye","year":"2009","unstructured":"Padhye, S. et al. Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Pharm. Res. 26, 2438\u20132445 (2009).","journal-title":"Pharm. Res."},{"key":"BFnm4310_CR36","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1182\/blood-2003-12-4369","volume":"105","author":"S Koschmieder","year":"2005","unstructured":"Koschmieder, S. et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 105, 324\u2013334 (2005).","journal-title":"Blood"},{"key":"BFnm4310_CR37","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","volume":"21","author":"L Li","year":"2012","unstructured":"Li, L. et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21, 266\u2013281 (2012).","journal-title":"Cancer Cell"},{"key":"BFnm4310_CR38","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1182\/blood-2007-09-112573","volume":"111","author":"M Copland","year":"2008","unstructured":"Copland, M. et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 111, 2843\u20132853 (2008).","journal-title":"Blood"},{"key":"BFnm4310_CR39","first-page":"129","volume":"1072","author":"P Angel","year":"1991","unstructured":"Angel, P. & Karin, M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim. Biophys. Acta 1072, 129\u2013157 (1991).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnm4310_CR40","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1038\/sj.onc.1210412","volume":"26","author":"DM Owens","year":"2007","unstructured":"Owens, D.M. & Keyse, S.M. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 26, 3203\u20133213 (2007).","journal-title":"Oncogene"},{"key":"BFnm4310_CR41","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1124\/pr.107.00106","volume":"60","author":"T Boutros","year":"2008","unstructured":"Boutros, T., Chevet, E. & Metrakos, P. Mitogen-activated protein (MAP) kinase\/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol. Rev. 60, 261\u2013310 (2008).","journal-title":"Pharmacol. Rev."},{"key":"BFnm4310_CR42","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1002\/j.1460-2075.1996.tb00731.x","volume":"15","author":"LA Groom","year":"1996","unstructured":"Groom, L.A., Sneddon, A.A., Alessi, D.R., Dowd, S. & Keyse, S.M. Differential regulation of the MAP, SAP and RK\/p38 kinases by Pyst1, a novel cytosolic dual-specificity phosphatase. EMBO J. 15, 3621\u20133632 (1996).","journal-title":"EMBO J."},{"key":"BFnm4310_CR43","doi-asserted-by":"publisher","first-page":"6749","DOI":"10.1074\/jbc.275.10.6749","volume":"275","author":"CC Fjeld","year":"2000","unstructured":"Fjeld, C.C., Rice, A.E., Kim, Y., Gee, K.R. & Denu, J.M. Mechanistic basis for catalytic activation of mitogen-activated protein kinase phosphatase 3 by extracellular signal-regulated kinase. J. Biol. Chem. 275, 6749\u20136757 (2000).","journal-title":"J. Biol. Chem."},{"key":"BFnm4310_CR44","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1084\/jem.20051794","volume":"203","author":"Q Zhao","year":"2006","unstructured":"Zhao, Q. et al. MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. J. Exp. Med. 203, 131\u2013140 (2006).","journal-title":"J. Exp. Med."},{"key":"BFnm4310_CR45","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1074\/jbc.272.7.4568","volume":"272","author":"DD Hirsch","year":"1997","unstructured":"Hirsch, D.D. & Stork, P.J. Mitogen-activated protein kinase phosphatases inactivate stress-activated protein kinase pathways in vivo. J. Biol. Chem. 272, 4568\u20134575 (1997).","journal-title":"J. Biol. Chem."},{"key":"BFnm4310_CR46","doi-asserted-by":"publisher","first-page":"12116","DOI":"10.1074\/jbc.272.18.12116","volume":"272","author":"PR Young","year":"1997","unstructured":"Young, P.R. et al. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J. Biol. Chem. 272, 12116\u201312121 (1997).","journal-title":"J. Biol. Chem."},{"key":"BFnm4310_CR47","doi-asserted-by":"publisher","first-page":"13681","DOI":"10.1073\/pnas.251194298","volume":"98","author":"BL Bennett","year":"2001","unstructured":"Bennett, B.L. et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA 98, 13681\u201313686 (2001).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFnm4310_CR48","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ccell.2015.05.008","volume":"28","author":"S Shojaee","year":"2015","unstructured":"Shojaee, S. et al. Erk negative feedback control enables pre-B cell transformation and represents a therapeutic target in acute lymphoblastic leukemia. Cancer Cell 28, 114\u2013128 (2015).","journal-title":"Cancer Cell"},{"key":"BFnm4310_CR49","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/nm.3930","volume":"21","author":"G Hrustanovic","year":"2015","unstructured":"Hrustanovic, G. et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat. Med. 21, 1038\u20131047 (2015).","journal-title":"Nat. Med."},{"key":"BFnm4310_CR50","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ccr.2012.02.018","volume":"21","author":"B Zhang","year":"2012","unstructured":"Zhang, B. et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell 21, 577\u2013592 (2012).","journal-title":"Cancer Cell"},{"key":"BFnm4310_CR51","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.ccr.2011.10.012","volume":"20","author":"D Reynaud","year":"2011","unstructured":"Reynaud, D. et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 20, 661\u2013673 (2011).","journal-title":"Cancer Cell"},{"key":"BFnm4310_CR52","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ccell.2015.04.004","volume":"27","author":"RS Welner","year":"2015","unstructured":"Welner, R.S. et al. Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. Cancer Cell 27, 671\u2013681 (2015).","journal-title":"Cancer Cell"},{"key":"BFnm4310_CR53","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","volume":"22","author":"KG Roberts","year":"2012","unstructured":"Roberts, K.G. et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 22, 153\u2013166 (2012).","journal-title":"Cancer Cell"},{"key":"BFnm4310_CR54","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker, B.J. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038\u20131042 (2001).","journal-title":"N. Engl. J. Med."},{"key":"BFnm4310_CR55","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1182\/blood-2011-06-361709","volume":"120","author":"KH Chang","year":"2012","unstructured":"Chang, K.H. et al. Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival. Blood 120, 800\u2013811 (2012).","journal-title":"Blood"},{"issue":"D1","key":"BFnm4310_CR56","doi-asserted-by":"publisher","first-page":"D917","DOI":"10.1093\/nar\/gkv1101","volume":"44","author":"FO Bagger","year":"2016","unstructured":"Bagger, F.O. et al. BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis. Nucleic Acids Res. 44 D1, D917\u2013D924 (2016).","journal-title":"Nucleic Acids Res."},{"key":"BFnm4310_CR57","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","volume":"109","author":"HG J\u00f8rgensen","year":"2007","unstructured":"J\u00f8rgensen, H.G., Allan, E.K., Jordanides, N.E., Mountford, J.C. & Holyoake, T.L. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 109, 4016\u20134019 (2007).","journal-title":"Blood"},{"key":"BFnm4310_CR58","doi-asserted-by":"publisher","unstructured":"Holyoake, T.L. & Vetrie, D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood \n                    https:\/\/dx.doi.org\/10.1182\/blood-2016-09-696013\n                    \n                   (2017).","DOI":"10.1182\/blood-2016-09-696013"},{"key":"BFnm4310_CR59","doi-asserted-by":"publisher","first-page":"14538","DOI":"10.1038\/srep14538","volume":"5","author":"M Kesarwani","year":"2015","unstructured":"Kesarwani, M. et al. Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. Sci. Rep. 5, 14538 (2015).","journal-title":"Sci. Rep."},{"key":"BFnm4310_CR60","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/nsmb.1486","volume":"15","author":"M Azam","year":"2008","unstructured":"Azam, M., Seeliger, M.A., Gray, N.S., Kuriyan, J. & Daley, G.Q. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat. Struct. Mol. Biol. 15, 1109\u20131118 (2008).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"BFnm4310_CR61","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/1471-2164-13-282","volume":"13","author":"K Komurov","year":"2012","unstructured":"Komurov, K., Dursun, S., Erdin, S. & Ram, P.T. NetWalker: a contextual network analysis tool for functional genomics. BMC Genomics 13, 282 (2012).","journal-title":"BMC Genomics"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nm.4310.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm.4310","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nm.4310.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T23:01:09Z","timestamp":1684450869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nm.4310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,20]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["BFnm4310"],"URL":"https:\/\/doi.org\/10.1038\/nm.4310","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,20]]},"assertion":[{"value":"11 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}